Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children

Share Article

The Firm is representing numerous men and boys in Risperdal lawsuits, all of whom allegedly developed gynecomastia (male breast growth) due to an elevation of prolactin caused by Risperdal.

Free Case Review
Our Firm is representing many Risperdal lawsuit plaintiffs who allegedly experienced gynecomastia, or male breast growth, allegedly due to increased prolactin levels caused by the drug.

As Risperdal lawsuits (http://www.risperdallawsuit2014.com/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes the publication of a new study which suggests that children treated with the medication may experience elevated levels of prolactin, a hormone linked to breast development and lactation. The study, which appears in International Clinical Psychopharmacology, looked at 34 children and adolescents who began treatment with risperidone, an antipsychotic medication sold in both generic versions and under the brand name Risperdal. Prior to treatment, the mean baseline prolactin level was 17.98ng/mL. Serum prolactin levels rose to an average 35.46ng/mL after 5.5 months of treatment, which the study authors characterized as a statistically significant difference. Overall, elevated levels of the hormone were detected in 20% of patients at baseline and 30% at follow-up.*

“Our Firm is representing many Risperdal lawsuit plaintiffs who allegedly experienced gynecomastia, or male breast growth, allegedly due to increased prolactin levels caused by the drug. Many of these clients are or were children when they began treatment with Risperdal,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.

Risperdal Litigation
Risperdal (risperidone) is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.**

Court records indicate more than 1,000 Risperdal lawsuits are now pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All of these lawsuits were filed on behalf of individuals who allegedly developed gynecomastia and other serious complications related to its use. Among other thing, plaintiffs allege Johnson & Johnson and its Janssen Pharmaceuticals unit improperly marketed Risperdal for off-label treatments, including for use in children. Risperdal gynecomastia plaintiffs also accuse the companies of failing to warn that patients using the drug may experience a rise in the body’s levels of prolactin. (In Re: Risperdal Litigation, Case Number 100300296).

In November 2013, Johnson & Johnson and Janssen struck an agreement with the U.S. Department of Justice to pay $2.2 billion to resolve criminal and civil charges regarding the marketing of several medications, including Risperdal. The companies pled guilty to promoting Risperdal for use in elderly dementia patients, but did not admit wrongdoing in resolving any of the other allegations, including those that involved the alleged improper marketing of the drug for pediatric indications (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Victims of gynecomastia allegedly caused by Risperdal may be entitled to pursue their own claim against Johnson & Johnson and Janssen. To learn more http://www.risperdallawsuit2014.com/risperdal-faqs/ about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*http://www.empr.com/the-effects-of-risperidone-on-prolactin-levels-in-children/article/388908/ empr.com, December 17, 2014
**accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, FDA, June 2009

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website